PRKAR1A Antibodies

cAMP-dependent protein kinase type I-alpha regulatory subunit (PRKAR1A)

Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells. .

Gene Information

Human
Gene Name:	PRKAR1A
Uniprot:	P10644
Entrez:	5573

Family

Belongs to:
cAMP-dependent kinase regulatory chain family

Alternative Names

cAMP-dependent protein kinase regulatory subunit RIalpha; cAMP-dependent protein kinase type I-alpha regulatory chain; cAMP-dependent protein kinase type I-alpha regulatory subunit; CAR; CNC; CNC1; MGC17251; PKA R1 alpha; PKA1; PKR1; PPNAD1; PRKAR1; protein kinase A type 1a regulatory subunit; protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specificextinguisher 1); Tissue-specific extinguisher 1; TSE1DKFZp779L0468

Molecular Weight

Mass (kDA):
42.982 kDA

Genomic Context

Human
Location:	17q24.2
Sequence:	17; NC_000017.11 (68413623..68551316)

Tissue Specificity

Four types of regulatory chains are found: I- alpha, I-beta, II-alpha, and II-beta. Their expression varies among tissues and is in some cases constitutive and in others inducible.

Subcellular Localizations

Cell membrane.

Diseases

• Neoplasms
• Carney Complex
• Myxoma
• Adenoma
• Cell Transformation, Neoplastic
• Malignant Neoplasms
• Multiple Endocrine Neoplasia
• Cushing Syndrome
• Pituitary Diseases
• Endocrine Gland Neoplasms
• Hyperplasia
• Tumors Of Adrenal Cortex
• Pituitary Neoplasms

• Adrenal Cortex Diseases
• Lentigo
• Spots On Skin
• Multiple Endocrine Neoplasia Type 1
• Pigmentation Disorders
• Carcinoma
• Neurilemmoma

Interacting Proteins

• AICDA
• C2orf88
• GABARAPL1
• PLEKHF2
• PRKACA

• PRKAR1B
• PRKX
• RFC2
• SET

Pathways

• Pigmentation
• Cell Cycle
• Pathogenesis
• Localization
• Cell Growth
• Secretion
• Cell Proliferation
• Cell Differentiation
• Oncogenesis
• Cortisol Secretion
• Excretion
• Transport
• Translation

• S Phase
• Protein Phosphorylation
• Meiosis
• Cell Activation
• Nuclear Transport
• Dna Repair
• Dna Replication

PTMs

• Phosphorylation
• Cleavage
• Methylation

• Acetylation
• Ribosylation
• Myristoylation

Research Areas

• Cancer

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/PRKAR1A

Best Uses Of The PRKAR1A Marker

Boster Bio founder Steven Boster invented the first ELISA kits in 1993. He was nicknamed "he who converts science into the lavatory". Since then, he has developed hundreds of primary antibodies and products for IHC and immunohistochemistry. He had built his company to be the largest catalog-based antibody company in China by the late 1990s. His PicoKineTM platform enabled him to develop the latest product, the high-sensitivity PRKAR1A ELISA set.

PDE11A

The PDE11A marker is a protein that is produced by the liver. It is also known by the name PDE11. It is known as PDE11A. This marker has many uses because it can be used as a precursor for several diseases. Here are some of PDE11A’s most effective uses. Below are just some of many uses for PDE11A. We will briefly cover the different types of PDE11A markings and their respective applications.

The invention is based on the discovery of differentially expressed markers in NASH and advanced liver fibrosis. These markers are expressed differently in the two types of disease. These markers can be used to diagnose and monitor the effects of treatments for NASH and other liver diseases. The invention is applicable to nonalcoholic fatty liver disease (NAFLD), hepatitis, fibrosis.

ACTH-secreting pituitary anadenomas

For pituitary adenomas, the PRKAR1A gene was extensively studied. It is a key player in the pituitary gland, which plays an important role in the production of hormones. Excess production of certain hormones can lead to a cascade effect, with other hormones being overproduced in response.

Researchers from the UCSF Medical Center San Francisco and other institutions used this gene to diagnose pituitary adenomas. These studies have shown that PRKAR1A gene expression is linked to the presence of tumor-regular lesions, a hallmark sign of cancer. This finding is not conclusive but is encouraging for future studies.

Moreover, the PRKAR1A gene is associated with the development of the Carney complex, a genetic disease characterized by hyperplasia of the endocrine organs, including the pituitary gland. The PRKAR1A mutation is associated with some cancers, including those that originate from the adrenal gland.

The PRKAR1A is a growthhormone, which promotes osteoblast and keratinocyte cell growth. Boster Bio's IGF1 receptor/IGF1R antibodies can be used widely in research and are backed with a quality warranty. They have a strong product line that is growing every month. Boster Bio's PRKAR1A kits contain antibodies that are patent-pending. They can be used with multiple species.

Testicular tumors

Although it's rare for testicular cancers to express tumor marker genes, approximately half of all testicular malignancies secrete at least one. These markers are found in most testis tumors. Germ cells in the testis have the potential to transform into different cell types and secrete different proteins during fetal development.

Although the exact mechanisms behind testicular cancer are not yet known, several different factors appear to contribute to its development. A testicular cancer may start as a non-invasive form of cancer called carcinoma in situ. This type may look abnormal under a microscope. However it has not spread beyond where sperm cells form. It may not progress to an invasive type of cancer, but it is worth noting that it will require further testing to determine the underlying cause.

These lesions are found in a 7-year old boy and raise suspicions of a rare genetic disorder called Carney complex. The genetic disorder is characterized multiple endocrine tumors and skin lesions. Genetic testing confirmed the diagnosis, which led to further investigation. This case proves that the PRKAR1A genes is responsible for a significant portion of all testicular tumours.

A molecular analysis of testicular cancers showed that mutations in PRKAR1A (a regulatory subunit of PKA) were present. The protein is an important effector molecule in multiple pathways of endocrine signaling. Biochemical studies have also shown that PKA activity increases after cAMP stimulation, which could explain pleiotropic manifestations.

Recent research revealed that a PRKAR1A variant was found in a patient who had LCCSCT. This mutation is a classic tumor suppressor gene, and its mutation is associated with the loss of a normal allele. This association was first discovered in a study of 53 related families over the past 20-years. It was reported in 15 out of 34 families that have CNC and seven cases of sporadic. However, the exact cause of the mutation or its role in malignancy is unknown.

PDE11A mutation

The PDE11A gene mutation has many potential uses, including the treatment of psychiatric conditions. PDE11A activity levels in human embryonic cells decreases if this gene is deleted. Patients with these variants have tumors that are often more aggressive than patients with normal PDE11A. These mutations can also cause extrasellar expansion.

One of PDE11A's most important uses is in the treatment and prevention of carney complex. This genetic disorder is caused by inactivating mutants of the PRKAR1A Gene. CNC's most common endocrine manifestation is Primary pigmented Nodular Adrenocortical Disease (PPNAD). PDE11A's protein-truncating mutations have been linked to numerous endocrine tumors such as adrenal and testicular cancer.

The PDE11A gene can be found on chromosome 31.2. It encodes a dual specific PDE that degrades both cAMP and GMP. Although the PDE11A mutation was initially associated with an ACTH-associated inherited disorder, further research has revealed that the PDE11A variant is polymorphic among the general population. This mutation was first found in adrenal tissues. A knockout mouse model of this disease has also shown impaired spermatogenesis.

Researchers have linked the PDE11A mutant to testicular germ cells tumors and prostatic carcinoma. Additionally, the PDEs affect cAMP levels and increase the risk of ACT. This mutation may also have other functions. Researchers believe this gene has important applications in the management of a variety disorders. The next step will be to find effective treatments.

Despite its complexity and many uses, the PDE11A variant is widely used. The mutation could be used to treat psychiatric disorders as well as tumor treatment. The discovery of this gene has helped many scientists. Its recombinant substances have the ability to activate and inhibit the PDE11A gene's cAMP, cGMP hydrolysis.

One of the most important regulator enzymes of intracellular CAMP is the PDE11A gene. Mutations of this gene have been found in patients with adrenocortical hyperplasia. It is also involved in the development tumors related the pituitary gland. For these reasons, it is important to identify the best uses of this mutation in patients with adrenocortical hyperplasia.